vTv Therapeutics (Nasdaq: VTVT) is a clinical-stage biopharmaceutical company that evolved from prior pharmaceutical research initiatives, focusing heavily on developing orally administered treatments for metabolic disorders, immunological conditions, and type 1 diabetes. Over the years, the company has advanced proprietary drug candidates like TTP399 through rigorous human trials, securing crucial FDA regulatory designations while collaborating with various global healthcare partners and institutional investors.